Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROSTASCINT vs POSLUMA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PROSTASCINT is a murine monoclonal antibody fragment (capromab pendetide) conjugated to the chelating agent glycyl-tyrosyl-lysyl-diethylenetriaminepentaacetic acid (GYK-DTPA) and labeled with indium-111. It binds to the intracellular epitope of prostate-specific membrane antigen (PSMA) expressed on prostate epithelial cells and is used for imaging prostate cancer.
PSMA-targeted radiotherapeutic agent; emits beta radiation causing DNA damage and cell death in PSMA-expressing cells.
FDA-approved: Diagnostic imaging in patients with biopsy-proven prostate cancer who are at high risk for pelvic lymph node metastases or with rising PSA after local therapy,Off-label: None well-established
Treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (m CRPC) who have received prior treatment with androgen receptor pathway inhibition and taxane-based chemotherapy.
5 m Ci (185 MBq) intravenously over 5 minutes, single dose.
1.85 MBq (0.05 m Ci)/kg intravenously as a single injection, followed by PET imaging approximately 60 minutes post-injection.
Terminal elimination half-life: 2.6 ± 0.7 days (requires 2 weeks for complete clearance; used for radioimmunodetection within 5–7 days post-injection)
Terminal elimination half-life: approximately 25–30 minutes for [68Ga]Ga-PSMA-11; rapid clearance from blood pool due to renal and hepatobiliary elimination.
Capromab pendetide is a monoclonal antibody fragment; metabolism is via catabolism to amino acids and small peptides. The indium-111 label is not metabolized and decays physically.
Predominantly excreted renally; no significant hepatic metabolism.
Renal: ~90% (predominantly as intact tracer), Fecal: <5%
Renal: 0% (not significantly eliminated via kidneys); Biliary/Fecal: predominantly eliminated via hepatobiliary system with fecal excretion of intact complex and metabolites, though precise % not established for human.
~90% (binding to plasma proteins, likely immunoglobulins and albumin)
Approximately 30–40% bound to plasma proteins (albumin minimally implicated; major binding to serum proteins not fully characterized).
5.5 L (not weight-adjusted; approximates intravascular space with slow distribution to extravascular tumor sites)
Central Vd ~ 0.2–0.3 L/kg (limited extravascular distribution; primarily confined to blood pool and highly perfused organs); high uptake in kidney, liver, spleen, salivary glands.
IV: 100% (not administered via other routes)
Intravenous: 100% (only route of administration).
No specific dose adjustment recommended; caution in severe renal impairment (GFR <30 m L/min) due to potential radiation clearance delay.
No formal dose adjustment recommendations; use with caution in severe renal impairment (e GFR <30 m L/min) due to potential increased radiation exposure.
No specific adjustment for Child-Pugh class; caution in severe hepatic impairment due to altered clearance.
No specific dose adjustment guidelines; no data in Child-Pugh classes.
Safety and efficacy not established; not recommended for pediatric patients.
No approved pediatric indication; safety and efficacy not established in patients <18 years.
No specific dose adjustment; follow standard adult dosing with consideration of renal function.
No specific dose adjustment; consider age-related renal function decline and monitor for adverse effects.
Not applicable.
None.
Risk of hypersensitivity reactions, including anaphylaxis,Use of murine antibodies may cause human anti-mouse antibody (HAMA) response, potentially affecting subsequent murine antibody-based diagnostics or therapeutics,Radiation exposure from indium-111; risk of secondary malignancies,Limited data in patients with renal impairment
Bone marrow suppression: Grade 3-4 thrombocytopenia, neutropenia, and anemia reported. Monitor blood counts.,Renal toxicity: Acute kidney injury and renal failure. Monitor renal function prior to and during therapy.,Hypersensitivity reactions: Monitor for signs and symptoms.,Radiation risks: Radiation exposure to patients, family, and healthcare providers; advise precautions.
Hypersensitivity to capromab pendetide, indium-111, or any component of the formulation,Pregnancy: potential fetal harm from radiation
Hypersensitivity to the active substance or any excipients.
No known food interactions. Maintain adequate hydration; no dietary restrictions required.
No specific food interactions. Maintain adequate hydration before and after administration. No fasting required.
PROSTASCINT (indium-111 capromab pendetide) is a murine monoclonal antibody labeled with indium-111 used for imaging. No adequate human data on fetal risk. Animal studies are not available. The radiopharmaceutical component emits radiation; fetal radiation exposure may increase the risk of congenital anomalies and childhood malignancies. Use in pregnant women is contraindicated unless potential benefit outweighs risks. First trimester exposure poses highest risk of teratogenesis; second and third trimester exposure may increase risk of childhood cancer.
POSLUMA (flortaucipir F 18) is a radioactive diagnostic agent. No human studies on fetal harm. Animal studies not conducted. All radiopharmaceuticals carry potential risk to fetus; radiation dose may cause fetal harm, especially during organogenesis (first trimester). Use only if benefit outweighs risk. Second and third trimester: lower risk but still consider cumulative radiation exposure.
Indium-111 is a radioactive isotope with a physical half-life of 2.8 days. Radioactive iodine may concentrate in breast milk. It is recommended to discontinue breastfeeding after administration. No M/P ratio available. To reduce radiation exposure to the infant, breastfeeding should be interrupted for a period based on the decay of indium-111 (typically at least 10 half-lives, i.e., 28 days). Pump and discard milk during this time.
Not studied in breastfeeding women. Flortaucipir F 18 is excreted in human milk; M/P ratio unknown. Advise temporary cessation of breastfeeding for a period based on physical half-life (109.8 min) and residual activity; typical recommendation: interrupt nursing for at least 4 hours post-administration to reduce infant exposure.
PROSTASCINT is contraindicated in pregnancy unless clearly needed. No pharmacokinetic data in pregnancy. Dose adjustment is not recommended as use should be avoided; if necessary, the minimum diagnostic activity should be used. Standard adult dose: 5 m Ci (0.5 mg antibody) intravenous. No adjustment for pregnancy-related pharmacokinetic changes due to lack of data.
No specific dose adjustments recommended; however, minimize radiation dose using the lowest effective activity. Pharmacokinetic changes in pregnancy (increased plasma volume, renal clearance) may alter distribution, but no data for flortaucipir F 18. Use standard weight-based dosing.
Prostascint (capromab pendetide) is a radiolabeled monoclonal antibody used for imaging prostate-specific membrane antigen (PSMA) in patients with prostate cancer. For optimal imaging, allow 72 hours post-injection for clearance of unbound antibody. Use with caution in patients with known murine protein allergy; pre-medicate with antihistamines if prior reaction. False-positive scans may occur in benign prostatic hyperplasia or inflammation. Ensure adequate hydration to promote renal excretion of the radiopharmaceutical.
POSLUMA (Flotufolastat F 18) is a radioactive diagnostic agent for PSMA PET imaging in prostate cancer. Administer as an IV bolus (3-7 m Ci) followed by saline flush. Image 1-2 hours post-injection. No special patient preparation needed; assess for ability to lie still. Evaluate injection site for extravasation to avoid image artifacts. Report all adverse reactions to FDA Med Watch.
This drug is a radioactive imaging agent that helps detect the spread of prostate cancer.,You will receive a single intravenous injection before your scan.,Drink plenty of water after the injection to help clear the radioactive material from your body.,Avoid close contact with pregnant women and young children for 24 hours after the scan.,Inform your doctor if you have had allergic reactions to mouse proteins or previous monoclonal antibody therapy.
This drug is a radioactive dye for PET scans to detect prostate cancer.,You will receive an injection into a vein, then wait about 1-2 hours before scanning.,Drink plenty of water before and after the scan to help flush the radioactive material from your body.,Tell your healthcare team if you are pregnant, breastfeeding, or have any allergies.,After the scan, avoid close contact with pregnant women and infants for several hours.,The radiation exposure is low and similar to other nuclear medicine tests.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROSTASCINT vs POSLUMA, answered by our medical review team.
PROSTASCINT is a Radiopharmaceutical Diagnostic Agent that works by PROSTASCINT is a murine monoclonal antibody fragment (capromab pendetide) conjugated to the chelating agent glycyl-tyrosyl-lysyl-diethylenetriaminepentaacetic acid (GYK-DTPA) and labeled with indium-111. It binds to the intracellular epitope of prostate-specific membrane antigen (PSMA) expressed on prostate epithelial cells and is used for imaging prostate cancer.. POSLUMA is a Radiopharmaceutical Diagnostic Agent that works by PSMA-targeted radiotherapeutic agent; emits beta radiation causing DNA damage and cell death in PSMA-expressing cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROSTASCINT and POSLUMA depend on the specific clinical indication. These are both Radiopharmaceutical Diagnostic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROSTASCINT is: 5 m Ci (185 MBq) intravenously over 5 minutes, single dose.. The standard adult dose of POSLUMA is: 1.85 MBq (0.05 m Ci)/kg intravenously as a single injection, followed by PET imaging approximately 60 minutes post-injection.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROSTASCINT and POSLUMA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROSTASCINT is classified as Category C. PROSTASCINT (indium-111 capromab pendetide) is a murine monoclonal antibody labeled with indium-111 used for imaging. No adequate human data on fetal risk. Animal studies are not a. POSLUMA is classified as Category C. POSLUMA (flortaucipir F 18) is a radioactive diagnostic agent. No human studies on fetal harm. Animal studies not conducted. All radiopharmaceuticals carry potential risk to fetus;. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.